4 results
Primary: long-term safety and efficacy of SAR236553 in high risk patients with an insufficiently controlled hypercholestolemia despite treatment with existing lipid modifying drugs.Secondary objectives: effect on individual lipids, development of…
To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by SAR236553 in comparison withezetimibe after 24 weeks of treatment in patients with hypercholesterolemia
To assess the immunomodulatory effects of erythromycin and clindamycin in healthy volunteers.
To evaluate the effect of digital self-monitoring-based management of relapsing and remitting multiple sclerosis on self-efficacy, clinical outcome measures and cost-effectiveness